Laurus Labs gets approval from USFDA for TLD

04 Feb 2019 Evaluate

Laurus Labs has received tentative approval from United States Food and Drug Administration (USFDA) under PEPFAR for Tenofovir / Lamivudine / Dolutegravir (TLD) 300/300/50mg fixed dose combination (FDC).

The TLD product will be available in the Generic form in low and middle income countries (LMIC). TLD is the preferred treatment recommended by US department of Health and Human Services Panel and also WHO has recommended TLD as one of the preferred first line regimen for the treatment of people living with HIV.

The company expects to commercialise this important medicine in the access markets and the product will be manufactured from the company's Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

586.45 15.65 (2.74%)
27-Dec-2024 15:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.90
Dr. Reddys Lab 1390.50
Cipla 1506.05
Lupin 2225.15
Zydus Lifesciences 971.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.